R. Ravasio, R. Viti, and A. S. Roscini, “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”, AboutOpen, vol. 10, no. 1, pp. 13–21, Jan. 2023.